Clinical Trials Logo

Clinical Trial Summary

Pulmonary Hypertension (PH) is a serious disease with a dismal prognosis when left untreated. Advances in medical therapy have improved survival according to recent registries and systematic reviews, but are associated with high healthcare costs. Earlier studies in Heidelberg, Germany showed good evidence for the effect of exercise training on improving exercise performance, quality of life and pulmonary hemodynamics in patients with pulmonary hypertension. The main objectives of the present project are: 1. to investigate the quality of the implementation of a standardized 3 week in-hospital exercise training program on markers of outcome and disease severity in PH-patients in Switzerland immediately after training and after 3 and 12 month. 2. to look whether training with hyperoxia vs. standard care might be more effective. This is a multicentre, randomized parallel-group trial where the intervention rehabilitation is delayed in one group so that they can serve as standard care controls for the others. In a nested single-centre randomized-controlled trial patent will additionally be randomized to receive either usual rehabilitation (UR) or rehabilitation with standardized supplemental oxygen therapy (SSOT) during nights and ergometer training. Patients will receive a PH specific rehabilitation program during 3 weeks followed by an instructed home-based training program for 12 weeks. Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights upon written informed consent.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02558582
Study type Interventional
Source University of Zurich
Contact Silvia Ulrich Somaini, PD Dr.
Phone 0041442552220
Email silvia.ulrich@usz.ch
Status Recruiting
Phase N/A
Start date September 1, 2015
Completion date December 2023

See also
  Status Clinical Trial Phase
Completed NCT04095286 - Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants Phase 1
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT02191137 - Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) Phase 4
Completed NCT01959828 - Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery Phase 3
Withdrawn NCT01202045 - Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients N/A
Completed NCT00963001 - Effect of Food on the Pharmacokinetics of Oral Treprostinil Phase 1
Completed NCT00963027 - Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil Phase 1
Completed NCT01121458 - Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed Phase 4
Terminated NCT00825266 - Insulin Resistance in Pulmonary Arterial Hypertension Phase 4
Terminated NCT00384865 - A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension Phase 2
Active, not recruiting NCT03926572 - Acute Decompensation of Pulmonary Hypertension N/A
Completed NCT02826252 - Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20) N/A
Completed NCT02545465 - A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice N/A
Recruiting NCT04498299 - Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
Active, not recruiting NCT02562235 - Riociguat in Children With Pulmonary Arterial Hypertension (PAH) Phase 3
Completed NCT02755298 - Chronic Clinical Effect of Acetazolamide Phase 2/Phase 3
Completed NCT02576002 - Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension) N/A
Terminated NCT03043976 - Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension N/A
Completed NCT01317134 - Endothelial Function in Patients With Pulmonary Arterial Hypertension N/A
Completed NCT01178073 - A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) Phase 3